Britain and America have forged a landmark bilateral deal that will keep zero import taxes on UK medicine shipments being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has pledged to increase expenditure on drugs through the National Health Service (NHS). This pledge guarantees that import taxes on these crucial exports will remain at nothing for a timeframe of 36 months.
This agreement follows recent statements to hike import taxes on branded drug imports, with potential rates mentioned reaching one hundred percent.
"This arrangement between the UK reinforces the worldwide climate for new treatments and brings long-overdue balance to American-British medicine commerce," an announcement noted.
Commercial Impact
Pharmaceuticals constitute one of the the United Kingdom's biggest export categories to the US, which is easily the biggest buyer for large UK drugmakers.
Export figures show that in the one-year period prior to the third quarter, the UK sold drugs worth billions to the US. This amount made up 17.4% of total UK exports in that timeframe.
"This deal safeguards work, boosts funding and facilitates the UK to become a global hub for life sciences," a government official stated.
Specific NHS Changes
The deal entails several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to raise total NHS spending on drugs from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be capped at 15%. Previously, refunds topped twenty percent.
Industry Background
The pact follows a long-running row between the drug companies and the UK government over medicine costs and approval rates.
This friction were exacerbated by arguments that US consumers were paying a premium for the identical medicines than people in the other developed nations.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while major investments have been announced toward American operations.
One official acknowledged that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a share of its resources over the last ten years.
